Defining Future Needs for Real-World Evidence in mCRC

Panelists identify gaps in current evidence and the need for more comprehensive real-world data to guide third-line therapy in metastatic colorectal cancer (mCRC).

They suggest future real-world evidence (RWE) should capture not only survival outcomes but also patient-reported quality of life, adherence, and broader safety signals.

Such data could enhance treatment personalization and support health system adoption of evidence-based third-line strategies.